Lactams

Medchemexpress LLC Acy-957 | 1609389-52-7 | 99.6% | 429.54 g/mol | C24H23N5OS | 50 MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

ACY-957 is an orally active, selective small-molecule inhibitor of histone deacetylase isoforms HDAC1 and HDAC2, used for research into epigenetic regulation. It shows potent activity against HDAC1 and HDAC2, reduced activity against HDAC3, and no measurable inhibition of several class II HDACs. The compound is supplied as a high-purity solid and is available in solution formats for assay use.

• Potent inhibition of HDAC1 and HDAC2.
• High selectivity over HDAC3 and class II HDACs.
• Suitable for in vitro and in vivo formulation protocols.
• High reported purity for reliable experimental results.
• Provided as a solid and as ready-to-use DMSO solutions.
• Documented storage and stability conditions for sample handling.

Medchemexpress LLC N-[2-amino-5-(2-thienyl)phenyl]-2-(1-piperazinyl)-6-quinolinecarboxamide | 1609389-52-7 | 99.6% | 429.54 g/mol | C24H23N5OS | 100 MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

ACY-957 is a small-molecule, orally active inhibitor selective for histone deacetylases HDAC1 and HDAC2, used in preclinical research to modulate epigenetic regulation and induce γ-globin expression. CAS 1609389-52-7; formula C24H23N5OS; molecular weight 429.54 g/mol.

• Selective inhibition of HDAC1 and HDAC2 (IC50 7 nM and 18 nM)
• Markedly reduced activity against HDAC3 (IC50 ≈ 1,300 nM), supporting class I selectivity
• Orally active in preclinical models, suitable for in vivo dosing studies
• High reported purity for research-grade material (~99.6%)
• Solid, light yellow to yellow form; stable when stored at -20 °C
• Used to study epigenetic regulation and hemoglobin induction in preclinical research

Medchemexpress LLC N-[2-amino-5-(2-thienyl)phenyl]-2-(1-piperazinyl)-6-quinolinecarboxamide | 1609389-52-7 | 99.6% | 429.54 g/mol | C24H23N5OS | 1 ML

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

ACY-957 is an orally active, selective small-molecule inhibitor of histone deacetylases HDAC1 and HDAC2 used in preclinical research to modulate epigenetic regulation and induce fetal hemoglobin expression. Reported IC50 values are 7 nM (HDAC1), 18 nM (HDAC2), and 1,300 nM (HDAC3). Supplied for in vitro and in vivo studies.

• Selective inhibition of HDAC1 and HDAC2 with low-nanomolar potency.
• Demonstrated activity in cellular models of globin gene induction.
• Orally active in preclinical pharmacology studies.
• Suitable for both in vitro and in vivo research applications.
• Characterized with vendor-provided purity and analytical data.

Medchemexpress LLC N-(2-amino-5-(thiophen-2-yl)phenyl)-2-(piperazin-1-yl)quinoline-6-carboxamide | 1609389-52-7 | MFCD30342405 | 99.6% | 429.54 g·mol⁻¹ | C24H23N5OS | 25 MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

ACY-957 is a small-molecule, orally active inhibitor selective for histone deacetylases HDAC1 and HDAC2 used in preclinical research. It potently inhibits HDAC1 (IC50 = 7 nM) and HDAC2 (IC50 = 18 nM), with substantially weaker activity against HDAC3 (IC50 = 1,300 nM), and shows no significant inhibition of HDAC4-HDAC9. The compound is provided as a purified research reagent for biochemical and cellular studies of epigenetic regulation.

• Potent HDAC1 inhibition (IC50 = 7 nM).
• Selective for HDAC1/2 over HDAC3 (IC50 HDAC2 = 18 nM; HDAC3 = 1,300 nM).
• Orally active profile reported in preclinical studies.
• Suitable for biochemical and cellular assays investigating epigenetic regulation.
• High chemical purity for reproducible experimental results.